When will a generic version of Teflaro be available?
Teflaro (ceftaroline fosamil) is still under patent and market exclusivity protection in the United States, so a generic version is not available yet. The expected timing depends on when key exclusivities expire and when a generic applicant gets approval. Publicly available timing estimates generally point to a window in the late-2020s rather than 2024–2026, but the exact “on-shelf” availability can vary by manufacturer and approval timing.
What could delay or speed up generic entry?
Generic availability can shift based on how courts and regulators handle exclusivity and patent disputes. If companies challenge patents or reach settlements, generic launch timing can move earlier or later. Even when exclusivity expires, the generic may not launch immediately if the first approved product’s labeling, manufacturing scale-up, or distribution timelines take additional time.
Why does exclusivity/patent status matter for “how long”?
In the U.S., a generic can only be marketed when it is legally cleared, which usually means at least one of these is true:
- related patents have expired or been ruled not infringed/not valid, or
- the relevant FDA exclusivity period has ended.
So the “how long” answer is tied to the last date of enforceable IP and exclusivity, not just the date a drug was first approved.
How to check the most up-to-date launch date
For the closest match to “when will I actually see it,” check:
- FDA’s Orange Book entry for Teflaro (lists patents and exclusivities tied to the reference product)
- FDA generic approval announcements (for the first ANDA approvals)
These are the sources that get updated when exclusivity ends and when an approved generic is imminent.
If you tell me the country you mean (U.S., Canada, UK, EU, etc.), I can narrow the timeline to the relevant patent/exclusivity framework for that market.